Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIMIPAC: Durvalumab, Tremelimumab, and Microwave Ablation in Locally Advanced Pancreatic Cancer
NCT04156087Phase 2Completed
- Start
- May 2020
- Primary completion
- Jan 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab and tremelimumab in pancreatic cancer (PC). Primary endpoint: Progression-free survival at 12 months. Started May 2020; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04156087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04156087.